David Thomson retweeted
🧵 Just published in @TheLancet: TORPEdO – the first phase 3 RCT designed specifically to test whether IMPT (proton beam) improves late function & QoL vs modern IMRT in oropharyngeal SCC.
Short answer: It doesn’t.
Long answer (with the numbers that matter) 👇
David Thomson retweeted
Come for the critically important data on protons for oropharyngeal cancer, stay for the beautifully written paper.
TORPEdO is out, and it is fascinating and instructive.
I will warn you upfront that this is a long thread, but there is a lot here to discuss!
thelancet.com/journals/lance…
David Thomson retweeted
No QoL difference with IMPT vs IMRT in oropharyngeal cancer in the TORPEdO 🇬🇧 trial.
How to explain the differences w/ @SJFrankMD 🇺🇸 trial? Planning? Patients? Crossover in the 🇺🇸 trial? Real absence of difference?
Cc @EmmaHall71 @
David Thomson retweeted
BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc @NRGonc
(h/t @yaoyu_md) @CJTsaiMDPhD @KaramLab @imrtlee @HenningWillers
emdgroup.com/en/news/xevinap…
David Thomson retweeted
Enjoyed making my debut at #ESTRO2024.. Lots of fun and a great experience presenting work on generalised competing event modelling in oropharynx cancer.. More to come in this area! #rstats #hncsm #radonc @drlorenmell @DrDThomson @TTFF_uk
David Thomson retweeted
Replying to @DrJohndeAlmeida @DavidSherMD @duvvuri_md @MCWardMD @RajasekaranMD @Penn_ENT @PennMedicine @DrNeilGross @HNSurgeon @TopfHNS @VinPaleri @KatieVanAbelMD @Dr_AliHosni
In our prior experience at @MSKCancerCenter @MSK_RadOnc, which included many cases of unknown primaries (and we often did not extensively look for the primary). 30Gy sterilized these supposedly microscopic foci. Ironically if you did find a tiny minute primary that area would wind up getting 60Gy postop instead. Regardless, in those treated with 30Gy to the pharyngeal axis, there’s no recurrence. In a way I sometimes prefer treating unknown primaries due to low dose/toxicities. Nowadays the treatment of unknown primaries can be much more tolerable. That’s why I did not think there’s a high value of extensively searching for microscopic primary.
@xrtGenomics @seanmmcbride @imrtlee
David Thomson retweeted
Replying to @PBlanchardMD
I draw something similar, but less anterior. On a node-positive neck in OPC, I just treat the IB nodal tissue anterior to IIA, but not going more anterior than the anterior aspect of the gland. Also feel sparing IB entirely is reasonable (this splits the difference).
David Thomson retweeted
Congrats @DrDThomson @dr_jm_price @KateGarcez and all involved in getting this over the line. A really important cohort of HNSCC patients with often limited options. Looking forward to opening the EORTC 2120 RAVINA trial here in Galway in 2024. Ye will have to come visit....
NIMRAD ph III trial in elderly/unfit LA HNSCC
-N=340
-IMRT 65 Gy/30fx +/- daily nimorazole
-endpoint freedom from locoregional progression, HR 0.50 in those with hypoxia score on 26-gene sig.≥ median)
-FFLRP HR 0.72, OS HR 0.96
-no benefit in HPV- subset
redjournal.org/article/S0360…
David Thomson retweeted
NEW: we need to talk about NHS staff retention.
At a time when Britain’s healthcare system is acutely short of workers, *1 in 7* UK-trained doctors are practising overseas. No other developed country is like this, which immediately tells you there’s a problem.
Let’s dig deeper:
David Thomson retweeted
Another epic story from Tex - thank you for sharing your experience with us!
#HeadandNeckCancerAwarenessDay
#PPIE @DrDThomson @AnnaRarity3
Today is #HeadAndNeckCancerAwarenessDay
Read about Tex from #Bolton who discovered a lump that turned out to be throat cancer after shaving off his beard.
He's now doing well after treatment and has completed this month's Bolton Ironman event!
More here:
gmcancer.org.uk/gmcancernews…
Amazing - well done Tex!
Today is #HeadAndNeckCancerAwarenessDay
Read about Tex from #Bolton who discovered a lump that turned out to be throat cancer after shaving off his beard.
He's now doing well after treatment and has completed this month's Bolton Ironman event!
More here:
gmcancer.org.uk/gmcancernews…
13
824
David Thomson retweeted
Do we need to provide adjuvant radiotherapy for low grade salivary gland cancers? Hard question - requires a large collaborative. Proud of the team from @ENT_Canada through our Canadian 🇨🇦 Head & Neck Collaborative doi.org/10.1002/cncr.34932 with 14 centers ! – at Toronto, Ontario
Some excellent recent papers discussed by the HN editors in this month’s Red Journal oncoscan. Enjoy!
Free link here:
authors.elsevier.com/a/1hPVL…
@MargalitMd @henson_md @cwilkeMDPhD @lachiemcd @IJROBP
David Thomson retweeted
Very often in healthcare, we make a massive effort to improve our delivery performance by changing our processes and practices. We should probably start much higher up in our knowledge structure by considering our paradigm - our beliefs about how to make change happen. If we do that, we start to frame the problem in different ways & adopt different principles for improvement. Graphic: adapted from @profhamel
David Thomson retweeted
It's arrived!!Very proud to see the delivery of this super book. This grew from an idea in lockdown with a wonderful collaboration of 56 amazing colleagues who kindly said "Yes!". I wish to thank everyone involved for all their support. So much to learn from every chapter.
Proud as the UKs first proton trial completes recruitment & ahead of schedule too!
Many thanks to the patients, and all involved. It’s been a huge team effort!
Very grateful to @CRUKresearch for funding the trial and @RTTQA_UK for their superb work.
The TORPEdO #ClinicalTrial reached its target enrolment of 205 participants this week. Thank you to all participants and colleagues involved in TORPEdO.
David Thomson retweeted
The TORPEdO #ClinicalTrial reached its target enrolment of 205 participants this week. Thank you to all participants and colleagues involved in TORPEdO.
Fantastic achievement for GM research and the @NIHRCRN_gman 👏
This Post is from an account that no longer exists. Learn more
7
698
David Thomson retweeted
At #ASCO23, our Dr. Renata Ferrarotto presented her Phase II trial results of a new immunotherapy and chemotherapy combination for cancer of the larynx. All 23 of the patients on the combination demonstrated good disease control. Learn more: bit.ly/429mZMf #EndCancer
































